Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
Tango Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Tango Therapeutics's total assets was $1.07B at Jun 30, 2026. For fiscal 2025 it was $398.69M, up 26.0% from the year before. The highest annual figure on record is $500.16M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $398.69M | +26.0% |
| FY2024 | Dec 31, 2024 | $316.49M | -21.4% |
| FY2023 | Dec 31, 2023 | $402.57M | -7.8% |
| FY2022 | Dec 31, 2022 | $436.47M | -12.7% |
| FY2021 | Dec 31, 2021 | $500.16M | +141.3% |
| FY2020 | Dec 31, 2020 | $207.25M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.07B | +351.4% |
| Q1 FY2026 | Mar 31, 2026 | $435.79M | +58.9% |
| Q4 FY2025 | Dec 31, 2025 | $398.69M | +26.0% |
| Q3 FY2025 | Sep 30, 2025 | $210.14M | -40.4% |
| Q2 FY2025 | Jun 30, 2025 | $237.89M | -37.6% |
| Q1 FY2025 | Mar 31, 2025 | $274.31M | -32.5% |
| Q4 FY2024 | Dec 31, 2024 | $316.49M | -21.4% |
| Q3 FY2024 | Sep 30, 2024 | $352.42M | -17.7% |
| Q2 FY2024 | Jun 30, 2024 | $381.45M | +0.6% |
| Q1 FY2024 | Mar 31, 2024 | $406.22M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | $402.57M | -7.8% |
| Q3 FY2023 | Sep 30, 2023 | $428.19M | -7.7% |
| Q2 FY2023 | Jun 30, 2023 | $379.33M | -15.4% |
| Q1 FY2023 | Mar 31, 2023 | $403.77M | -14.4% |
| Q4 FY2022 | Dec 31, 2022 | $436.47M | -12.7% |
| Q3 FY2022 | Sep 30, 2022 | $464.16M | -12.4% |
| Q2 FY2022 | Jun 30, 2022 | $448.40M | +167.6% |
| Q1 FY2022 | Mar 31, 2022 | $471.53M | +180.2% |
| Q4 FY2021 | Dec 31, 2021 | $500.16M | +141.3% |
| Q3 FY2021 | Sep 30, 2021 | $530.14M | +214.8% |
| Q2 FY2021 | Jun 30, 2021 | $167.55M | – |
| Q1 FY2021 | Mar 31, 2021 | $168.26M | – |
| Q4 FY2020 | Dec 31, 2020 | $207.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $168.38M | – |
See a number that looks wrong?